Clinical Trial Update: Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) [Phase 3]

View source ↗

Summary

Phase 3 EPIC trial evaluating purified poloxamer 188 for vaso-occlusive crisis in sickle cell disease has completed; no efficacy results are provided in the sni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease
• Vaso-occlusive Crisis

Drugs mentioned

• Purified Poloxamer 188 (poloxamer 188)

Snippet

Sponsor: Mast Therapeutics, Inc. | Conditions: Vaso-occlusive Crisis, Sickle Cell Disease | Phase 3 | Status: COMPLETED